Kyntra Bio Inc KYNB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $6.50
- Day Range
- $6.30–6.64
- 52-Week Range
- $6.30–12.13
- Bid/Ask
- $6.00 / $6.80
- Shares Outstanding
- 4.05M
- Market Cap
- $25.55M
- Volume/Avg
- 26,079 / 17,219
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 34
- Website
- https://www.kyntrabio.com
Valuation
|
Metric
|
KYNB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 5.70 |
Price/Cash Flow | 0.23 |
Price/Earnings
KYNB
Financial Strength
|
Metric
|
KYNB
|
|---|---|
Quick Ratio | 2.54 |
Current Ratio | 2.69 |
Interest Coverage | −2.79 |
Quick Ratio
KYNB
Profitability
|
Metric
|
KYNB
|
|---|---|
Return on Assets (Normalized) | −56.37% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
KYNB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#Ll?Ncn | LOCK|<S?Hd | $128B | |||
| Moderna Inc
MRNA
| LOCK|B&M><h | LOCK|Pp$ | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?#y@H<s | LOCK|?S?b< | $76B | |||
| argenx SE ADR
ARGX
| LOCK|>dfS@< | LOCK|P@ | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|r%!<>L | LOCK|<P | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#c@%X!# | LOCK|zWtFf | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Gl<%nYx | LOCK|fYsf@ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|#RP%Q<R | LOCK|MR^ | $24B | |||
| Incyte Corp
INCY
| LOCK|zR%D$Jl | LOCK|$P> | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|pkSWhd | LOCK|J#! | $15B |
United States